SecSonar.com

Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Xenon Pharmaceuticals Inc. (XENE) is a Biotechnology company based in CA with a market capitalization of $4.3B. Free cash flow was negative at -$279.9M. This page tracks XENE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

CA · 316 employees · IPO Nov 5, 2014

Valuation

Valuation & price

$54.39 · as of May 17, 2026 · -13.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

7.44

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$60.96$45.63$30.30Jul 25Dec 25Jul 26Jul 7, 25$31.83Jul 9, 25$32.68Jul 11, 25$32.21Jul 15, 25$31.48Jul 17, 25$32.12Jul 21, 25$31.49Jul 23, 25$31.19Jul 25, 25$30.30Jul 29, 25$30.87Jul 31, 25$30.54Aug 4, 25$33.16Aug 6, 25$34.27Aug 11, 25$34.11Aug 13, 25$37.67Aug 15, 25$38.23Aug 19, 25$37.36Aug 21, 25$38.18Aug 25, 25$38.14Aug 27, 25$38.87Aug 29, 25$38.71Sep 3, 25$38.83Sep 5, 25$39.21Sep 9, 25$37.51Sep 11, 25$37.22Sep 16, 25$35.66Sep 18, 25$37.76Sep 22, 25$37.35Sep 24, 25$36.59Sep 26, 25$37.98Sep 30, 25$40.15Oct 2, 25$39.20Oct 6, 25$39.55Oct 8, 25$39.25Oct 10, 25$39.64Oct 14, 25$40.57Oct 16, 25$42.17Oct 21, 25$43.04Oct 23, 25$41.20Oct 27, 25$41.89Oct 29, 25$42.30Oct 31, 25$41.92Nov 4, 25$39.09Nov 6, 25$38.30Nov 10, 25$38.41Nov 12, 25$39.68Nov 14, 25$40.76Nov 18, 25$40.61Nov 20, 25$40.27Nov 25, 25$43.94Nov 28, 25$44.72Dec 2, 25$42.88Dec 4, 25$44.61Dec 8, 25$44.53Dec 10, 25$43.44Dec 12, 25$44.06Dec 16, 25$43.00Dec 18, 25$43.23Dec 22, 25$46.08Dec 24, 25$45.01Dec 29, 25$44.33Jan 2, 26$44.49Jan 6, 26$41.00Jan 8, 26$41.22Jan 12, 26$41.23Jan 14, 26$41.58Jan 16, 26$39.98Jan 21, 26$41.00Jan 23, 26$41.76Jan 27, 26$42.39Jan 29, 26$41.76Feb 2, 26$41.45Feb 4, 26$41.15Feb 9, 26$42.43Feb 11, 26$42.76Feb 13, 26$41.48Feb 18, 26$42.51Feb 20, 26$42.23Feb 24, 26$44.79Feb 26, 26$44.92Mar 2, 26$42.55Mar 4, 26$43.05Mar 6, 26$41.94Mar 10, 26$60.61Mar 12, 26$57.90Mar 17, 26$55.20Mar 19, 26$55.17Mar 23, 26$54.42Mar 25, 26$55.57Mar 27, 26$54.48Mar 31, 26$58.15Apr 2, 26$56.85Apr 7, 26$57.65Apr 9, 26$58.59Apr 13, 26$58.60Apr 15, 26$58.88Apr 17, 26$59.70Apr 22, 26$56.65Apr 24, 26$55.24Apr 28, 26$54.53Apr 30, 26$56.04May 4, 26$57.40May 6, 26$58.59May 8, 26$56.44May 12, 26$55.00May 14, 26$56.00May 18, 26$53.71May 20, 26$54.68May 22, 26$54.17May 28, 26$54.79Jun 1, 26$53.41Jun 3, 26$53.46Jun 5, 26$51.73Jun 9, 26$52.79Jun 11, 26$52.19Jun 15, 26$52.40Jun 17, 26$53.20Jun 22, 26$54.79Jun 24, 26$55.58Jun 26, 26$59.74Jul 2, 26$60.96
$30.3052-week range$62.76
Loading valuation history…

Fundamentals

Key fundamentals

$4.3B

Market cap

—

Revenue growth (YoY)

66.1%

Gross margin

-$279.9M

Free cash flow (USD)

-$540.9M

Net debt

Net cash position

1.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.8MFY 2017$311.0KFY 2018$0.00FY 2019$6.8MFY 2020$32.2MFY 2021$18.4MFY 2022$9.4MFY 2023$0.00FY 2024$0.00FY 2025$7.5M
$1.8M$7.5M

Free cash flow by year

2016 → 2025

FY 2016$-19.8MFY 2017$-29.0MFY 2018$-35.2MFY 2019$-5.9MFY 2020$-50.8MFY 2021$-71.6MFY 2022$-101.3MFY 2023$-150.9MFY 2024$-184.5MFY 2025$-279.9M
-$19.8M-$279.9M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 202566.1%
100.0%66.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $63K · 10b5-1 PlanCannon Gillian · Director · $63.2KJun 8, 2026Filing
  • Insider sellInsider Sell $70K · 10b5-1 PlanPATOU GARY · Director · $70.3KJun 8, 2026Filing
  • 8-K eventEquity Incentive Plan EstablishedJun 3, 2026Filing
  • 8-K eventQ1 2026 Financial ResultsMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventEquity Incentive Plan AmendedApr 13, 2026Filing

Questions

Frequently asked questions

What is Xenon Pharmaceuticals Inc.'s market cap?

Xenon Pharmaceuticals Inc. (XENE) has a market capitalization of $4.3B.

What is XENE's P/E ratio?

A meaningful P/E ratio is not available for XENE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is XENE's price-to-book (P/B) ratio?

XENE trades at 7.44 times book value per share.

Are insiders buying XENE stock?

SEC Form 4 filings show no open-market insider buys at Xenon Pharmaceuticals Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

SYRE

Spyre Therapeutics, Inc.

$4.4B

TVTX

Travere Therapeutics, Inc.

$4.4B

LGND

Ligand Pharmaceuticals Incorporated

$4.7B

NAMS

NewAmsterdam Pharma Company N.V.

$3.9B

CAI

Caris Life Sciences, Inc.

$4.7B

CPRX

Catalyst Pharmaceuticals, Inc.

$3.8B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.